TGIA x Congenica genomic data interpretation
TGIA Bioinformatics
- TGIA has the exclusive authorization of technical transfer and industry-academy cooperation from NHRI.
- TGIA utilize Illumina DRAGEN/nVIDIA GPU hardware acceleration technology for secondary analysis.
- 5,000 WGS/WES cases of big data generated from Flagship Program of Precision Medicine for Asia Pacific Biomedical Silicon Valley.
- Undertake the cooperation network and clinical experiences of 14 medical center from Flagship Program of Precision Medicine for Asia Pacific Biomedical Silicon Valley.
- Integrate, optimize, and customize the clinical decision support service for interpretation of genetic and rare diseasessuitable for users in Taiwan and in line with global networks.
Congenica genomic data interpretation
- A genomic data interpretation company from Welcome Sanger Institute/UK Biobank.
- ntegral player in the UK’s 100,000 Genomes Project, and subsequently being chosen as the exclusive clinical decision support platform and sole provider of genomic data analysis for NHS Genomic Medicine Centers.
- CE marked under the In Vitro Diagnostics (IVD) directive, and received certification in ISO and HIPAA, Congenica platform provides the standardized and stringently regulated quality-controlled products.
- Specialist modules of Neuro and Prenatal analysis to optimize the analysis in high-need indications with expert curation.
- Phenotype-based prioritization of variants with the literature supported Exomiser algorithm, enhancing the average clinical diagnostic rate from 30% to 43%.
Accelerating the widespread of genetic testing in inheritable and rare disease. Take WGS genetic testing as example, the Congenica platform can speed up the overall tertiary analysis time from 16 hours to 5-30 minutes.
